课题基金 / 基金详情

Health IT generated PROs to Improve Outcomes in Cirrhosis

Health IT generated PROs to Improve Outcomes in Cirrhosis
健康 IT 生成 PRO 来改善肝硬化的治疗结果
批准号:
10374779
负责人:
Jasmohan S Bajaj
金额:
$39.46万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-06-11 至 2024-03-31

项目摘要

项目成果

Jasmohan S Bajaj的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Patients with cirrhosis are prone to clinical and psycho-social issues that manifest as patient-reported outcomes (PRO), which can independently predict hospitalization, re-hospitalizations and death. Our group has studied the impact of these PRO extensively. With the increasing spread of health-related electronic devices, the relevance of health IT in the management of chronic diseases such as cirrhosis is paramount. The team has already developed and used several health IT advances to educate patients and their caregivers in inpatient and outpatient settings. These tools include Patient Buddy to prevent avoidable readmissions and EncephalApp Stroop to detect and guide therapy for cognitive dysfunction in cirrhosis. However the evaluation of these tools in a multi-center study that adapts to the status of the patients and their caregivers is required. The central hypothesis is that cirrhotic patients randomized to health IT interventions that elicit PROs in a structured outpatient setting will have a significantly greater reduction in hospital readmissions because of improved communication with their medical teams compared to standard of care regardless of scheduled return outpatient visits. This will be tested using the following two specific aims in three centers (Virginia Commonwealth University, Richmond VA Medical Center and Mayo Clinic). Specific Aim 1: To evaluate in a multi-center, randomized trial the effectiveness of PROs elicited using PatientBuddy and EncephalApp with and without scheduled outpatients return visits on the prevention of avoidable 30 day readmissions in patients with cirrhosis and their caregivers compared to standard of care. We will include 450 total cirrhotic patients and 450 caregivers (150 patients and 150 caregivers per center), who will be followed for 30 days post-discharge. The groups will be randomized 1:1:1 into a standard of care group, a group receiving health IT interventions who will receive PatientBuddy and EncephalApp with as-needed follow-up and another group that receives the same health IT interventions along with scheduled outpatient visits and calls within 30 days of discharge. Avoidable readmissions will be adjudged using a blinded adjudication committee and the differences between the three groups will be compared. Specific aim 2: To incorporate the opinion of key stakeholders (patients, caregivers and nurse managers) towards improving the Patient Buddy App in the prevention of readmission in cirrhosis. As part of this trial, we will also elicit feedback regarding the ease, safety and personal effectiveness of these interventions as well as their personal comfort and educational value of the App with and without the scheduled outpatient follow-up, from the patients, caregivers and administering staff. This will be compared between centers and used to enhance the Patient Buddy App in collaboration with our technology partners. The updated App will then be available for future studies in larger cirrhosis populations.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.cgh.2020.03.033
发表时间: 2020-12
期刊: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子: --
作者: [Bajaj JS, Duarte-Rojo A, Xie JJ, Acharya C, Wade JB, Robles C, Thacker LR, Flud C, Fagan A, Garcia-Saenz-de-Sicilia M, White MB, Kelly M, Nguyen V, Gavis EA, Vargas HE]
通讯作者: Vargas HE
DOI: 10.2196/24639
发表时间: 2021-04-09
期刊: Journal of medical Internet research
影响因子: 7.4
作者: [Acharya C, Sehrawat TS, McGuire DB, Shaw J, Fagan A, McGeorge S, Olofson A, White MB, Gavis E, Kamath PS, Bergstrom L, Bajaj JS]
通讯作者: Bajaj JS
DOI: 10.1007/s11901-020-00510-4
发表时间: 2020-03
期刊: Current hepatology reports
影响因子: --
作者: [Shaw J, Tate V, Hanson J, Bajaj JS]
通讯作者: Bajaj JS
DOI: 10.1002/ygh2.390
发表时间: 2020-03
期刊: GastroHep
影响因子: --
作者: [Bajaj JS, Acharya C, Sikaroodi M, Gillevet PM, Thacker LR]
通讯作者: Thacker LR
Fecal microbiota transplant for Alcohol-Associated Cirrhosis
  • 批准号:
    10703378
  • 项目类别:
  • 资助金额:
    $54.6万
  • 财政年份:
    2022
  • 负责人:
    Jasmohan S Bajaj
  • 依托单位:
Fecal microbiota transplant for Alcohol-Associated Cirrhosis
  • 批准号:
    10444624
  • 项目类别:
  • 资助金额:
    $54.85万
  • 财政年份:
    2022
  • 负责人:
    Jasmohan S Bajaj
  • 依托单位:
BCCMA: Targeting Gut Microbiome in Gastrointestinal and Liver Diseases in US Veterans; CMA4: At the Crossroads of the Gut Microbiome, Cirrhosis, and PTSD
Liver Cirrhosis Network: Clinical Research Centers
  • 批准号:
    10487561
  • 项目类别:
  • 资助金额:
    $37.54万
  • 财政年份:
    2021
  • 负责人:
    Jasmohan S Bajaj
  • 依托单位:
国内基金
海外基金
基于多重计算全息片(Computer-generated Hologram,CGH)的光学非球面干涉绝对检验方法研究
  • 批准号:
    62375132
  • 项目类别:
    面上项目
  • 资助金额:
    54.00万元
  • 批准年份:
    2023
  • 负责人:
    马骏
  • 依托单位:
面向人工智能生成内容的风险识别与治理策略研究
  • 批准号:
    72304290
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    向安玲
  • 依托单位: